62 related articles for article (PubMed ID: 12122963)
1. Impact of different anticancer regimens on biomarkers of angiogenesis in patients with advanced hepatocellular cancer.
Treiber G; Wex T; Malfertheiner P
J Cancer Res Clin Oncol; 2009 Feb; 135(2):271-81. PubMed ID: 18642029
[TBL] [Abstract][Full Text] [Related]
2. Clinical pharmacokinetics of imatinib.
Peng B; Lloyd P; Schran H
Clin Pharmacokinet; 2005; 44(9):879-94. PubMed ID: 16122278
[TBL] [Abstract][Full Text] [Related]
3. Imatinib mesylate in Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon alpha.
Tóthová E; Kafková A; Fricová M; Benová B; Kirschnerová G; Tóthová A
Neoplasma; 2005; 52(1):63-7. PubMed ID: 15739029
[TBL] [Abstract][Full Text] [Related]
4. [Efficacy of imatinib mesylate, a specific inhibitor of BCR/ABL tyrosine kinase, on chronic myeloid leukemia in blast phase].
Zhang GC; Zheng D; Li QH; Li XH; Cai CC; Luo SK; Li J; Peng AH; Tong XZ; Tan EX; Hong WD
Ai Zheng; 2004 Dec; 23(12):1696-9. PubMed ID: 15601563
[TBL] [Abstract][Full Text] [Related]
5. Imatinib: new preparation. For Chronic myeloid leukaemia: further assessment required.
Prescrire Int; 2003 Apr; 12(64):49-52. PubMed ID: 12669727
[TBL] [Abstract][Full Text] [Related]
6. Approval summary: imatinib mesylate capsules for treatment of adult patients with newly diagnosed philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase.
Johnson JR; Bross P; Cohen M; Rothmann M; Chen G; Zajicek A; Gobburu J; Rahman A; Staten A; Pazdur R
Clin Cancer Res; 2003 Jun; 9(6):1972-9. PubMed ID: 12796358
[TBL] [Abstract][Full Text] [Related]
7. Imatinib mesylate.
Baker DE
Rev Gastroenterol Disord; 2002; 2(2):75-86. PubMed ID: 12122963
[TBL] [Abstract][Full Text] [Related]
8. Imatinib mesylate (Glivec, Gleevec) in the treatment of chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors (GIST).
Hochhaus A
Ann Hematol; 2004; 83 Suppl 1():S65-6. PubMed ID: 15124676
[No Abstract] [Full Text] [Related]
9. [Molecular targeted treatment--new treatment strategy for patients with chronic myeloid leukemia].
Usui N
Rinsho Byori; 2004 Feb; 52(2):136-44. PubMed ID: 15027317
[TBL] [Abstract][Full Text] [Related]
10. The role of therapeutic drug monitoring of imatinib in patients with chronic myeloid leukemia and metastatic or unresectable gastrointestinal stromal tumors.
Teng JF; Mabasa VH; Ensom MH
Ther Drug Monit; 2012 Feb; 34(1):85-97. PubMed ID: 22215488
[TBL] [Abstract][Full Text] [Related]
11. Clinical pharmacokinetics of imatinib mesylate.
Levêque D; Maloisel F
In Vivo; 2005; 19(1):77-84. PubMed ID: 15796158
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]